This level of efficacy approaching the kind of weight loss previously seen only with bariatric surgery has been a game changer in obesity treatment
It comes as little surprise, then, to learn that retailers are indeed seeing the GLP-1-inspired effects of this trend in both foot traffic and sales figures
The first phase 3 retatrutide trial, TRIUMPH-4, top-line data announced today Retatrutide, a triple GLP-1,GIP, glucagon agonist studied in patients with obesity and osteoarthritis 28.7% weight loss at 68 weeks Reduced key cardiometabolic risk markers non-HDL cholesterol, triglycerides, and hsCRP Highest dose lowered systolic BP by 14 mmHg Reduced WOMAC pain scores by up to an average of 4.5 points (75.8%) and significantly improved measures of physical function GI side effects most common adverse event We now await 7 additional phase 3 trials in other obesity related comorbidities Retatrutide May Redefine Multi-Receptor Therapeutics Triple agonism (GLP-1 + GIP + glucagon) isnt just about adding more receptors this distinct mechanism can boost energy expenditure, not just suppress appetite
Every product is manufactured under strict quality controls to ensure consistent performance, safety, and peace of mind with every use
Dietary Strategies to Maintain Healthy Iron Levels Iron Supplementation: When and How to Take It Safely Key Takeaways When to Seek Professional Advice FAQs Understanding the Connection Between Wegovy and Iron Levels Wegovy, containing the active ingredient semaglutide, works by mimicking a naturally occurring hormone called GLP-1 that regulates appetite and food intake
Endocrinology & Metabolism Clinics of North America 4
